Korea United Pharm said it has signed a five-year supply and distribution agreement with MCQ, a Thai-based pharmaceutical company specializing in drug distribution, for Levotics CR Tab., a mucoactive drug.

Levotics CR Tab. is an incrementally modified drug (IMD) that improves compliance and convenience by reducing the number of doses from three times a day to two times a day.

Under the accord, MCQ will conduct local clinical trials for the marketing authorization of Levotics CR Tab. in Thailand and will be responsible for sales and marketing of the product.

Korea United Pharm expects to receive up to 69.6 billion won ($52.1 million), including a technology fee of about 400 million won, for the next five years.

“We will receive a separate technical fee for providing technical support to MCQ,” a Korea United Pharm official said. “This reflects the value of the company’s superior technology.”

The official stressed that the supply agreement comes after the company has been actively pursuing global expansion since its establishment by supplying various medicines, such as anticancer drugs, to overseas countries.

The company has recently accelerated its global expansion by expanding its export competitiveness with IMDs and plans to continue to explore avenues to enter major countries, including the U.S. and Europe, by leveraging the competitiveness of its IMDs.